LifeVantage Q1 FY27 revenue drops 22% and swings to net loss, challenging recent growth narrative

What happened

LifeVantage reported first quarter fiscal 2027 revenue of $37.1 million, a 22.0% decline from the prior year, with both the Americas and Asia/Pacific & Europe segments dropping over 20% each. The company swung to a net loss of $0.02 per diluted share versus net income of $0.17 per share a year earlier, while adjusted earnings per share fell to $0.05 from $0.18 and adjusted EBITDA halved to $1.9 million from $3.9 million. This sharp top-line contraction reverses the growth inflection driven by the MindBody GLP-1 System that lifted fiscal 2025 results and suggests weakening demand or field momentum in the direct selling channel. The decline is broad-based geographically and likely reflects a combination of product fatigue, consultant attrition, or increased competition in the weight management and supplement categories. The company's thin operating margins provide little buffer, and the negative free cash flow in recent quarters further underscores deteriorating financial flexibility.

Implication

The 22% revenue decline and swing to a net loss indicate that the MindBody GLP-1 momentum has faded quickly, raising questions about the sustainability of the product's appeal and the health of the MLM consultant network. With adjusted EBITDA nearly halved and free cash flow negative in the most recent quarter, the company's ability to maintain dividends and buybacks while investing in compliance and product development is under pressure. The risk of further active account declines and potential regulatory scrutiny on weight loss claims becomes more acute when sales are contracting. While the balance sheet remains net cash, the deterioration in operating performance reduces the margin of safety that was already thin relative to the intrinsic value estimate of $7.08 per share. Investors should await evidence of stabilization in active accounts and revenue before considering any position, and any additional negative signals would justify a downgrade to SELL.

Thesis delta

The previous WAIT thesis was predicated on monitoring the durability of MindBody GLP-1 growth and active account trends. This quarter's sharp revenue decline and loss indicate that the positive inflection from fiscal 2025 has reversed, moving the thesis toward a more negative bias. The thesis shifts from 'WAIT for evidence of sustainable growth' to 'WAIT with heightened skepticism, as downside risks are materializing'; a further quarter of similar deterioration would warrant a SELL.